Online Webinar 2019 - New FDA Guidance for Direct-to-Consumer Promotional Labeling and Advertisements Live Webinar
Topics/Call fo Papers
Overview
The FDA released a new draft guidance document in October 2018 on the topic of efficacy and risk information in direct-to-consumer promotional labeling and advertisements. The guidance document provides industry with advice on how to present effectiveness and risk information in consumer ads in such a way that it is easily understood by consumers. It is essential that a product’s benefits and risk are clear, concise and informative. Therefore, the goal of the new guidance is to provide industry professionals with the knowledge necessary to ensure that prescription drug promotional materials are truthful and not misleading; especially, in regard to a product’s benefits and risks.
Session Highlights
Topic 1: Review History of DTC Promotional Labeling
• A Decade of Evolving Regulation
Topic 2: Review DTC Promotional Labeling Regulatory Requirements
• Food Drug & Cosmetics Act (FDCA)
• 21 CFR 202
Topic 3: Review Concepts Detailed in the October 2018 FDA Guidance
• How to present quantitative risk data so that it is understood by the consumer
• Proper use of Visual Aids to illustrate quantitative efficacy or risk information
Topic 4: Understand the consequences of Non-Compliance
• Review potential outcomes for Non-Compliance
• Review Recent Regulatory Actions Regarding DTC Promotional Labeling Non-Compliance
o FDA Enforcement Actions: Warning Letters, Consent Decrees, Injunctions, Seizers
Why should you attend
This course will provide a detailed overview of the new FDA guidance document in order to educate participates on the agency’s recommendations and expectations in regard to Direct-to Consumer promotional labeling.
Course Participates will:
Understand the regulatory requirements governing DTC promotional labeling
Understand how to apply those requirements
Explain the new regulatory expectations regarding how to present quantitative risk data
Understand the regulatory expectations regarding visual aids
Understand the consequences of non-compliance to DTC promotional labeling regulations
Who will benefit
Marketing managers
Regulatory affairs managers
In-house legal counsel
Third-party consultants
Own Label distributors
International trade managers
Product specification developers
Corporate web managers
Quality Assurance Departments
Regulatory Affairs Departments
Medical Affairs Departments
Marketing Departments
Program & Portfolio Management
Commercial/Corporate Compliance Departments
Instructor Profile
Ms. Thomas has over two decades of cGMP hands-on industry experience in both pharmaceutical and medical device manufacturing operations. Her experience covers all Quality Systems; as well as, all areas of validation; including, process/product validation, facilities validation, CSV and 21 CFR Part 11, test method validation, equipment/automated processes and cleaning validation.
Utilizing strategic thinking, risk based approaches, and Lean principles, she has demonstrated success in steering and managing complex projects within the pharmaceutical and medical device industries.
The FDA released a new draft guidance document in October 2018 on the topic of efficacy and risk information in direct-to-consumer promotional labeling and advertisements. The guidance document provides industry with advice on how to present effectiveness and risk information in consumer ads in such a way that it is easily understood by consumers. It is essential that a product’s benefits and risk are clear, concise and informative. Therefore, the goal of the new guidance is to provide industry professionals with the knowledge necessary to ensure that prescription drug promotional materials are truthful and not misleading; especially, in regard to a product’s benefits and risks.
Session Highlights
Topic 1: Review History of DTC Promotional Labeling
• A Decade of Evolving Regulation
Topic 2: Review DTC Promotional Labeling Regulatory Requirements
• Food Drug & Cosmetics Act (FDCA)
• 21 CFR 202
Topic 3: Review Concepts Detailed in the October 2018 FDA Guidance
• How to present quantitative risk data so that it is understood by the consumer
• Proper use of Visual Aids to illustrate quantitative efficacy or risk information
Topic 4: Understand the consequences of Non-Compliance
• Review potential outcomes for Non-Compliance
• Review Recent Regulatory Actions Regarding DTC Promotional Labeling Non-Compliance
o FDA Enforcement Actions: Warning Letters, Consent Decrees, Injunctions, Seizers
Why should you attend
This course will provide a detailed overview of the new FDA guidance document in order to educate participates on the agency’s recommendations and expectations in regard to Direct-to Consumer promotional labeling.
Course Participates will:
Understand the regulatory requirements governing DTC promotional labeling
Understand how to apply those requirements
Explain the new regulatory expectations regarding how to present quantitative risk data
Understand the regulatory expectations regarding visual aids
Understand the consequences of non-compliance to DTC promotional labeling regulations
Who will benefit
Marketing managers
Regulatory affairs managers
In-house legal counsel
Third-party consultants
Own Label distributors
International trade managers
Product specification developers
Corporate web managers
Quality Assurance Departments
Regulatory Affairs Departments
Medical Affairs Departments
Marketing Departments
Program & Portfolio Management
Commercial/Corporate Compliance Departments
Instructor Profile
Ms. Thomas has over two decades of cGMP hands-on industry experience in both pharmaceutical and medical device manufacturing operations. Her experience covers all Quality Systems; as well as, all areas of validation; including, process/product validation, facilities validation, CSV and 21 CFR Part 11, test method validation, equipment/automated processes and cleaning validation.
Utilizing strategic thinking, risk based approaches, and Lean principles, she has demonstrated success in steering and managing complex projects within the pharmaceutical and medical device industries.
Other CFPs
- Effective Purchasing and Supplier Controls for Medical Device Manufacturers
- Patient Access to Health Information, Texting, and E-mail — HIPAA Requirements for Easy, Low-cost Access by Jim Sheldon-Dean
- Live Webinar Employee Travel and Expense Reimbursement Schemes: Detection and Prevention
- 10th World Congress on Biosensors and Bioelectronics
- 2nd International Conference on Bipolar Disorder: Depression and Psychiatry
Last modified: 2019-05-01 20:35:13